> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Disc Medicine Gets Fast Track for MWTX-003
- URL: https://www.fdaweb.com/disc-medicine-gets-fast-track-for-mwtx-003/
- Published: 2023-09-20T12:00:00.000Z
- Updated: 2026-09-14T18:57:25.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5155375

FDA has granted Disc Medicine a fast-track designation for MWTX-003 and its use for treating patients with polycythemia vera (PV). The investigational, anti-TMPRSS6 (Transmembrane Serine Protease 6, also known as Matriptase-2) monoclonal antibody is designed to increase hepcidin production and suppress serum iron, according to the company. Preclinical studies of MWTX-003 showed an increase in hepcidin production and suppression of serum iron levels in animal models, it says. Disc plans to initiate a Phase 1 study later this year, adding that initially it will be evaluated for PV and later for other hematologic conditions.

PV is a chronic and rare myeloproliferative neoplasm characterized by the abnormal production of red blood cells, according to the company. This overproduction alters blood viscosity, causing it to thicken and placing patients at an elevated risk of cardiovascular and thromboembolic events, such as heart attack and stroke, it says. It affects about 150,000 patients in the U.S.